Vaccine Contract Manufacturing Market Size, Share, Trends, Growth Outlook

Vaccine Contract Manufacturing Market is estimated to increase at a growth rate of 12.1% CAGR over the forecast period from 2024 to 2030.

The global Vaccine Contract Manufacturing Marketstudy analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments including By Vaccine (Attenuated Vaccine, Inactivated Vaccine, Subunit vaccines, Toxoid Vaccines, DNA Vaccines), By Workflow (Downstream, Upstream), By Application (Human Use, Veterinary).

An introduction to Vaccine Contract Manufacturing Market in 2024

Providing life-saving support for patients with severe respiratory or cardiac failure, the Veno-Venous Extracorporeal Life Support (VV-ECLS) Devices Market offers advanced extracorporeal membrane oxygenation (ECMO) systems designed to oxygenate and remove carbon dioxide from the blood outside the body, temporarily supporting pulmonary function and allowing time for lung recovery or transplantation. VV-ECLS devices consist of a membrane oxygenator, blood pump, cannulas, and circuit components, enabling veno-venous bypass and gas exchange via peripheral or central vascular access. These devices are used in critical care settings, including intensive care units (ICUs) and cardiac surgery centers, for patients with acute respiratory distress syndrome (ARDS), severe pneumonia, or refractory respiratory failure, providing mechanical circulatory support until lung function improves or a suitable treatment option is available. This market serves cardiothoracic surgeons, critical care physicians, perfusionists, and respiratory therapists managing patients with acute respiratory failure, offered by medical device manufacturers specializing in ECMO technology. With the increasing prevalence of respiratory emergencies, the growing demand for advanced life support therapies, and ongoing advancements in ECMO technology, the Veno-Venous Extracorporeal Life Support Devices Market continues to evolve. As clinicians optimize patient selection criteria, refine ECMO management protocols, and enhance device performance and safety features, the market drives innovation in VV-ECLS technology, improving outcomes for critically ill patients worldwide.

Vaccine Contract Manufacturing Market Trend: Increasing Outsourcing of Vaccine Manufacturing

One prominent trend in the Vaccine Contract Manufacturing market is the increasing outsourcing of vaccine manufacturing by pharmaceutical companies and biotechnology firms. With the growing demand for vaccines driven by infectious disease outbreaks, pandemics, and routine immunization programs, vaccine manufacturers are faced with the need to expand production capacity, accelerate time-to-market, and manage supply chain complexities. Outsourcing vaccine manufacturing to contract manufacturing organizations (CMOs) offers advantages such as cost savings, flexibility, and access to specialized expertise and infrastructure. Pharmaceutical companies are leveraging the capabilities of CMOs to meet fluctuating demand, mitigate manufacturing risks, and focus on core competencies such as research and development. This trend towards outsourcing reflects the evolving dynamics of the vaccine industry and drives market growth in the Vaccine Contract Manufacturing market.

Vaccine Contract Manufacturing Market Driver: Increasing Global Vaccination Initiatives and Pandemic Preparedness

A significant driver in the Vaccine Contract Manufacturing market is the increasing emphasis on global vaccination initiatives and pandemic preparedness efforts worldwide. Governments, international organizations, and public health agencies are prioritizing vaccination programs to prevent the spread of infectious diseases, reduce disease burden, and achieve public health objectives such as disease eradication and outbreak control. The COVID-19 pandemic has underscored the critical importance of vaccine development and manufacturing capabilities in responding to global health emergencies. As countries strive to enhance vaccine production capacity, ensure vaccine supply security, and expedite vaccine distribution, there is a growing reliance on contract manufacturing partners to support vaccine manufacturing scale-up, technology transfer, and regulatory compliance. The focus on global vaccination initiatives and pandemic preparedness drives demand for contract manufacturing services and fosters market growth in the Vaccine Contract Manufacturing market.

Vaccine Contract Manufacturing Market Opportunity: Expansion into Emerging Markets and Vaccine Types

An emerging opportunity in the Vaccine Contract Manufacturing market lies in the expansion into emerging markets and the production of a diverse range of vaccine types. Emerging economies are witnessing increasing demand for vaccines to address endemic diseases, expand immunization coverage, and strengthen healthcare infrastructure. Contract manufacturing organizations have the opportunity to establish strategic partnerships and manufacturing facilities in emerging markets to cater to local vaccine needs, enhance access to vaccines, and support global health goals. Additionally, there is potential to diversify vaccine manufacturing capabilities to include a broader range of vaccine types such as mRNA vaccines, viral vector vaccines, and recombinant protein vaccines. By expanding into emerging markets and offering expertise in manufacturing various vaccine platforms, CMOs can capitalize on opportunities for market expansion, innovation, and collaboration in the Vaccine Contract Manufacturing market.

Vaccine Contract Manufacturing Market Market Segmentation

By Vaccine Type
Attenuated Vaccine
Inactivated Vaccine
Subunit vaccines
Toxoid Vaccines
DNA Vaccines
By Workflow
Downstream
-Fill & Finish Operations
-Analytical & QC studies
-Packaging
Upstream
-Mammalian Expression Systems
-Bacterial Expression Systems
-Yeast Expression Systems
-Baculovirus/Insect Expression Systems
-Others
By Application
Human Use
Veterinary

Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)

Vaccine Contract Manufacturing Market Companies

Ajinomoto Bio-Pharma Services
Catalent
Charles River Laboratories International Inc
CJ CheilJedang Corp
Curia Global
Emergent BioSolutions Inc
Fujifilm Holdings Corp
Gedeon Richter
ICON PLC
IDT Biologika GmbH
Lonza Group AG
Recipharm AB

Reasons to Buy the Vaccine Contract Manufacturing Market Study

• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Vaccine Contract Manufacturing Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Vaccine Contract Manufacturing Market industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.

TABLE OF CONTENTS

1 Introduction to 2024 Vaccine Contract Manufacturing Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Analyzed
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain

2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations

3 Executive Summary
3.1 Global Vaccine Contract Manufacturing Market Size Outlook, $ Million, 2021 to 2030
3.2 Vaccine Contract Manufacturing Market Outlook by Type, $ Million, 2021 to 2030
3.3 Vaccine Contract Manufacturing Market Outlook by Product, $ Million, 2021 to 2030
3.4 Vaccine Contract Manufacturing Market Outlook by Application, $ Million, 2021 to 2030
3.5 Vaccine Contract Manufacturing Market Outlook by Key Countries, $ Million, 2021 to 2030

4 Market Dynamics
4.1 Key Driving Forces of Vaccine Contract Manufacturing Industry
4.2 Key Market Trends in Vaccine Contract Manufacturing Industry
4.3 Potential Opportunities in Vaccine Contract Manufacturing Industry
4.4 Key Challenges in Vaccine Contract Manufacturing Industry

5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global Vaccine Contract Manufacturing Market Share by Company (%), 2023
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook

6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts

7 Global Vaccine Contract Manufacturing Market Outlook by Segments
7.1 Vaccine Contract Manufacturing Market Outlook by Segments, $ Million, 2021- 2030
By Vaccine Type
Attenuated Vaccine
Inactivated Vaccine
Subunit vaccines
Toxoid Vaccines
DNA Vaccines
By Workflow
Downstream
-Fill & Finish Operations
-Analytical & QC studies
-Packaging
Upstream
-Mammalian Expression Systems
-Bacterial Expression Systems
-Yeast Expression Systems
-Baculovirus/Insect Expression Systems
-Others
By Application
Human Use
Veterinary

8 North America Vaccine Contract Manufacturing Market Analysis and Outlook To 2030
8.1 Introduction to North America Vaccine Contract Manufacturing Markets in 2024
8.2 North America Vaccine Contract Manufacturing Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Vaccine Contract Manufacturing Market size Outlook by Segments, 2021-2030
By Vaccine Type
Attenuated Vaccine
Inactivated Vaccine
Subunit vaccines
Toxoid Vaccines
DNA Vaccines
By Workflow
Downstream
-Fill & Finish Operations
-Analytical & QC studies
-Packaging
Upstream
-Mammalian Expression Systems
-Bacterial Expression Systems
-Yeast Expression Systems
-Baculovirus/Insect Expression Systems
-Others
By Application
Human Use
Veterinary

9 Europe Vaccine Contract Manufacturing Market Analysis and Outlook To 2030
9.1 Introduction to Europe Vaccine Contract Manufacturing Markets in 2024
9.2 Europe Vaccine Contract Manufacturing Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Vaccine Contract Manufacturing Market Size Outlook by Segments, 2021-2030
By Vaccine Type
Attenuated Vaccine
Inactivated Vaccine
Subunit vaccines
Toxoid Vaccines
DNA Vaccines
By Workflow
Downstream
-Fill & Finish Operations
-Analytical & QC studies
-Packaging
Upstream
-Mammalian Expression Systems
-Bacterial Expression Systems
-Yeast Expression Systems
-Baculovirus/Insect Expression Systems
-Others
By Application
Human Use
Veterinary

10 Asia Pacific Vaccine Contract Manufacturing Market Analysis and Outlook To 2030
10.1 Introduction to Asia Pacific Vaccine Contract Manufacturing Markets in 2024
10.2 Asia Pacific Vaccine Contract Manufacturing Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Vaccine Contract Manufacturing Market size Outlook by Segments, 2021-2030
By Vaccine Type
Attenuated Vaccine
Inactivated Vaccine
Subunit vaccines
Toxoid Vaccines
DNA Vaccines
By Workflow
Downstream
-Fill & Finish Operations
-Analytical & QC studies
-Packaging
Upstream
-Mammalian Expression Systems
-Bacterial Expression Systems
-Yeast Expression Systems
-Baculovirus/Insect Expression Systems
-Others
By Application
Human Use
Veterinary

11 South America Vaccine Contract Manufacturing Market Analysis and Outlook To 2030
11.1 Introduction to South America Vaccine Contract Manufacturing Markets in 2024
11.2 South America Vaccine Contract Manufacturing Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Vaccine Contract Manufacturing Market size Outlook by Segments, 2021-2030
By Vaccine Type
Attenuated Vaccine
Inactivated Vaccine
Subunit vaccines
Toxoid Vaccines
DNA Vaccines
By Workflow
Downstream
-Fill & Finish Operations
-Analytical & QC studies
-Packaging
Upstream
-Mammalian Expression Systems
-Bacterial Expression Systems
-Yeast Expression Systems
-Baculovirus/Insect Expression Systems
-Others
By Application
Human Use
Veterinary

12 Middle East and Africa Vaccine Contract Manufacturing Market Analysis and Outlook To 2030
12.1 Introduction to Middle East and Africa Vaccine Contract Manufacturing Markets in 2024
12.2 Middle East and Africa Vaccine Contract Manufacturing Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Vaccine Contract Manufacturing Market size Outlook by Segments, 2021-2030
By Vaccine Type
Attenuated Vaccine
Inactivated Vaccine
Subunit vaccines
Toxoid Vaccines
DNA Vaccines
By Workflow
Downstream
-Fill & Finish Operations
-Analytical & QC studies
-Packaging
Upstream
-Mammalian Expression Systems
-Bacterial Expression Systems
-Yeast Expression Systems
-Baculovirus/Insect Expression Systems
-Others
By Application
Human Use
Veterinary

13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
Ajinomoto Bio-Pharma Services
Catalent
Charles River Laboratories International Inc
CJ CheilJedang Corp
Curia Global
Emergent BioSolutions Inc
Fujifilm Holdings Corp
Gedeon Richter
ICON PLC
IDT Biologika GmbH
Lonza Group AG
Recipharm AB
14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise

By Vaccine Type
Attenuated Vaccine
Inactivated Vaccine
Subunit vaccines
Toxoid Vaccines
DNA Vaccines
By Workflow
Downstream
-Fill & Finish Operations
-Analytical & QC studies
-Packaging
Upstream
-Mammalian Expression Systems
-Bacterial Expression Systems
-Yeast Expression Systems
-Baculovirus/Insect Expression Systems
-Others
By Application
Human Use
Veterinary